Evidence map›Paper›PMID 37093133›Full record

ArticleInvestigative ophthalmology & visual science2023

Insights Into PROM1-Macular Disease Using Multimodal Imaging.

Maarjaliis Paavo, Winston Lee, Rait Parmann, Jose Ronaldo Lima de Carvalho, Jana Zernant, Stephen H Tsang, Rando Allikmets, Janet R Sparrow

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Maarjaliis PaavoDepartments of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Winston LeeDepartments of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Rait ParmannDepartments of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Jose Ronaldo Lima de CarvalhoDepartments of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Jana ZernantDepartments of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Stephen H TsangDepartments of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Rando AllikmetsDepartments of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Janet R SparrowDepartments of Ophthalmology, Columbia University Medical Center, New York, New York, United States.
Columbia University Irving Medical Center · USUniversity of Helsinki · FI

Funding

Instrumentation, Fabrication, and Design CoreP30EY019007 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Xin Zhang · 2010 to 2026
$12.9M
IMPACT OF LIPOFUSCIN IN RETINAL PIGMENT EPITHELIAL CELLSR01EY012951 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SPARROW, JANET RUTHE · 2000 to 2024
$8.9M
MEASURES OF HUMAN RECEPTOR AND POST RECEPTOR ACTIVITYR01EY009076 · NEI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI BIRCH, DAVID G, HOOD, DONALD C. · 1991 to 2021
$8.3M
Toward mechanism- and gene-based therapies for retinal degenerationR01EY018213 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Stephen H Tsang · 2008 to 2026
$6.6M
Gene Silencing and Gene Editing in PhototransductionR01EY024698 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Stephen H Tsang · 2015 to 2026
$4.7M
Quantitative Fundus Autofluorescence in Retinal DisordersR01EY024091 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SPARROW, JANET RUTHE · 2014 to 2022
$3.4M
Precision medicine for ABCA4 disease: modifier allelesR01EY028203 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALLIKMETS, RANDO L · 2018 to 2021
$2.3M
Stargardt disease with low lipofuscinR01EY028954 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALLIKMETS, RANDO L · 2019 to 2022
$2.1M
Instrumentation for Animal-Dedicated In Vivo Eye Imaging by Spectral Domain Optical Coherence TomographyS10OD028637 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SPARROW, JANET RUTHE · 2020 to 2020
$297k
NEI NIH HHS P30 EY019007NEI NIH HHS R01 EY009076NEI NIH HHS R01 EY012951NEI NIH HHS R01 EY018213NEI NIH HHS R01 EY024091NEI NIH HHS R01 EY024698NEI NIH HHS R01 EY028203NEI NIH HHS R01 EY028954NIH HHS S10 OD028637
6 · The paper itself

Abstract

Purpose: To describe the features of genetically confirmed PROM1-macular dystrophy in multimodal images. Methods: Thirty-six (36) eyes of 18 patients (5-66 years; mean age, 42.4 years) were prospectively studied by clinical examination and multimodal imaging. Short-wavelength autofluorescence (SW-AF) and quantitative fundus autofluorescence (qAF) images were acquired with a scanning laser ophthalmoscope (HRA+OCT, Heidelberg Engineering) modified by insertion of an internal autofluorescent reference. Further clinical testing included near-infrared autofluorescence (NIR-AF; HRA2, Heidelberg Engineering) with semiquantitative analysis, spectral domain-optical coherence tomography (HRA+OCT) and full-field electroretinography. All patients were genetically confirmed by exome sequencing. Results: All 18 patients presented with varying degrees of maculopathy. One family with individuals affected across two generations exhibited granular fleck-like deposits across the posterior pole. Areas of granular deposition in SW-AF and NIR-AF corresponded to intermittent loss of the ellipsoid zone, whereas discrete regions of hypoautofluorescence corresponded with a loss of outer retinal layers in spectral-domain optical coherence tomography scans. For 18 of the 20 eyes, qAF levels within the macula were within the 95% confidence intervals of healthy age-matched individuals; nor was the mean NIR-AF signal increased relative to healthy eyes. Conclusions: Although PROM1-macular dystrophy (Stargardt disease 4) can exhibit phenotypic overlap with recessive Stargardt disease, significantly increased SW-AF levels were not detected. As such, elevated bisretinoid lipofuscin may not be a feature of the pathophysiology of PROM1 disease. The qAF approach could serve as a method of early differential diagnosis and may help to identify appropriate disease targets as therapeutics become available to treat inherited retinal disease.

Indexed as

Macular DegenerationRetinal DystrophiesAC133 AntigenAdultFluorescein AngiographyFundus OculiHumansMultimodal ImagingOptical ImagingRetinaRetinal Pigment EpitheliumStargardt DiseaseTomography, Optical CoherenceAC133 AntigenPROM1 protein, human

Identifiers

PMID37093133
PMCPMC10148657
OpenAlexW4366819473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.